Algeria



I. Epidemiological profile

Population (UN Population Division)	2017 %
Number of active foci	0 -
Number of people living within active foci	0 -
Malaria free (0 cases)	41.3M 100
Total	41.3M

Parasites and vectors		
Major plasmodium species:	P.falciparum: 0 (%), P.vivax: 0 (%)	
Major anopheles species:	An. multicolor, An. labranchiae, An. sergentii, An. hispaniola	
Reported indigenous confirm	ed cases (health facility):	0
Confirmed cases at communit	ty level:	-
Confirmed cases from private	sector:	-
Indigenous deaths:		0

II. Intervention policies and strategies

Intervention	Policies/Strategies	Yes/ No	Year adopted
ITN	ITNs/LLINs distributed free of charge	No	2000
	ITNs/LLINs distributed to all age groups	No	-
IRS	IRS is recommended	Yes	1980
	DDT is used for IRS	No	-
Larval control	Use of Larval Control	Yes	-
IPT	IPT used to prevent malaria during pregnancy	-	=.
Diagnosis	Patients of all ages should receive diagnostic test	-	-
	Malaria diagnosis is free of charge in the public sector	Yes	1968
Treatment	ACT is free for all ages in public sector	Yes	-
	The sale of oral artemisinin-based monotherapies (oAMTs)	has never been allowed	-
	Single dose of primaquine (0.25 mg base/kg) is used as gametocidal medicine for P. falciparum	Yes	-
	Primaquine is used for radical treatment of P. vivax	Yes	-
	G6PD test is a requirement before treatment with primaquine	No	-
	Directly observed treatment with primaquine is undertaken	Yes	-
	System for monitoring of adverse reaction to antimalarials exists	No	-
Surveillance	ACD for case investigation (reactive)	Yes	-
	ACD at community level of febrile cases (pro-active)	No	-
	Mass screening is undertaken	No	-
	Uncomplicated P. falciparum cases routinely admitted	Yes	-
	Uncomplicated P. vivax cases routinely admitted	Yes	-
	Case and foci investigation undertaken	Yes	1980
	Case reporting from private sector is mandatory	Yes	-

First-line treatment of unconfirmed malaria First-line treatment of P. falciparum For treatment failure of P. falciparum Treatment of severe malaria Treatment of P. vivax Dosage of primaquine for radical treatment of P. vivax Type of RDT used Therapeutic efficacy tests (clinical and parasitological failure, %) Medicine Year Min Median Max Follow-up Resistance status by insecticide class (2010-2017) and use of cla Insecticide class Years (%) sites ¹	P.f + all sp	- - - - - - (14 days) Decies (Combo)
For treatment failure of P. falciparum Treatment of severe malaria Treatment of P. vivax Dosage of primaquine for radical treatment of P. vivax Type of RDT used Therapeutic efficacy tests (clinical and parasitological failure, %) Medicine Year Min Median Max Follow-up Resistance status by insecticide class (2010-2017) and use of cla	0.25 mg P.f + all sp	pecies (Combo)
Treatment of severe malaria Treatment of P. vivax Dosage of primaquine for radical treatment of P. vivax Type of RDT used Therapeutic efficacy tests (clinical and parasitological failure, %) Medicine Year Min Median Max Follow-up Resistance status by insecticide class (2010-2017) and use of cla	0.25 mg P.f + all sp	pecies (Combo)
Treatment of P. vivax Dosage of primaquine for radical treatment of P. vivax Type of RDT used Therapeutic efficacy tests (clinical and parasitological failure, %) Medicine Year Min Median Max Follow-up Resistance status by insecticide class (2010-2017) and use of cla	0.25 mg P.f + all sp	pecies (Combo)
Dosage of primaquine for radical treatment of P. vivax Type of RDT used Therapeutic efficacy tests (clinical and parasitological failure, %) Medicine Year Min Median Max Follow-up Resistance status by insecticide class (2010-2017) and use of cla	0.25 mg P.f + all sp	pecies (Combo)
Type of RDT used Therapeutic efficacy tests (clinical and parasitological failure, %) Medicine Year Min Median Max Follow-up Resistance status by insecticide class (2010-2017) and use of cla	P.f + all sp	pecies (Combo)
Therapeutic efficacy tests (clinical and parasitological failure, %) Medicine Year Min Median Max Follow-up Resistance status by insecticide class (2010-2017) and use of cla		
Medicine Year Min Median Max Follow-up Resistance status by insecticide class (2010-2017) and use of cla		Casaisa
Medicine Year Min Median Max Follow-up Resistance status by insecticide class (2010-2017) and use of cla		Casaisa
		Species
		.,
Insecticide class Years (%) sites ¹	iss for malaria vec	tor control (201
	Vectors ²	Used ³
Carbamates	-	No
Organochlorines	-	No
Organophosphates	-	No
Pyrethroids	-	Yes
¹ Percent of sites for which resistance confirmed and total number of sites that	reported data (n)	
² Principal vectors that exhibited resistance		
³ Class used for malaria vector control in 2017		